Ken Furudate

LLM-PathwayCurator converts pathway enrichment results into auditable claims with quality assurance, showing variable coverage across cancer cohorts.

LLM-scCurator improves zero-shot cell-type annotation by reducing biological noise and enhancing accuracy without training data.

This study examines how chemotherapy affects clonal diversity and mutation patterns in hematopoietic stem cells, finding that melphalan increases mutational burden and promotes clonal aging, potentially leading to therapy-related myeloid neoplasms.

This paper establishes a humanized mouse model of glioblastoma using patient-derived xenografts to study immune infiltration and tumor heterogeneity, finding immune cell profiles similar to recurrent human GBM.